TherapeuticsMD (TXMD) Misses Q4 EPS by 2c

TherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $18.68 million versus the consensus estimate of $28.98 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order